Two Sigma Advisers
PSTV

Two Sigma Advisers’s Plus Therapeutics PSTV Stock Holding History

Two Sigma Advisers’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-86
Closed -$9.31K – 2604
2023
Q1 		$9.31K Sell
86
-1
-1% -$135 ﹤0.01% 2545
2022
Q4 		$10.4K Sell
87
-26
-23% -$4.14K ﹤0.01% 2458
2022
Q3 		$19K Sell
113
-19
-14% -$4.24K ﹤0.01% 2444
2022
Q2 		$27K Sell
132
-79
-37% -$19.7K ﹤0.01% 2529
2022
Q1 		$79K Sell
211
-493
-70% -$188K ﹤0.01% 2536
2021
Q4 		$277K Buy
704
+540
+329% +$311K ﹤0.01% 2168
2021
Q3 		$117K Sell
164
-304
-65% -$232K ﹤0.01% 2311
2021
Q2 		$449K Buy
468
+305
+187% +$276K ﹤0.01% 1982
2021
Q1 		$147K Buy
163
+97
+147% +$98.3K ﹤0.01% 2396
2020
Q4 		$50K Buy
+66
New +$56.4K ﹤0.01% 2317
2015
Q1 		– Hold
0
– -$5K – 2295
2014
Q4 		– Hold
0
– – – 2393

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Two Sigma Advisers's PSTV Position: Q2 2023 in Review

Two Sigma Advisers sold out of Plus Therapeutics (PSTV) in Q2 2023, closing a stake of 86 shares — an estimated $9.31K sold.

Two Sigma Advisers first reported a position in PSTV in Q4 2020 and held it in 10 quarters. The position peaked at $449K in Q2 2021. 6 funds tracked by Wall St. Rank hold PSTV as of Q2 2023.

  • Two Sigma Advisers reported no remaining Plus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 86 Plus Therapeutics shares in Q2 2023, an estimated $9.31K.
  • Two Sigma Advisers first reported a position in Plus Therapeutics in Q4 2020 and held it in 10 quarters.
  • Two Sigma Advisers's Plus Therapeutics position peaked at $449K in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Plus Therapeutics as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.